Early Phase Cancer Immunotherapy
This volume, a state-of-the-art review of early phase clinical trials for cancer immunotherapy, discusses biomarker selection, combinatorial strategies and their safety or toxicity, determination of Phase 2 dosing, endpoints in the setting of radiographic
- PDF / 5,541,494 Bytes
- 336 Pages / 439.42 x 683.15 pts Page_size
- 111 Downloads / 250 Views
Sandip Pravin Patel Razelle Kurzrock Editors
Early Phase Cancer Immunotherapy
Current Cancer Research
Series Editor Wafik El-Deiry
More information about this series at http://www.springer.com/series/7892
Sandip Pravin Patel • Razelle Kurzrock Editors
Early Phase Cancer Immunotherapy
Editors Sandip Pravin Patel Division of Hematology/Oncology Department of Medicine University of California, San Diego Moores Cancer Center La Jolla, CA, USA
Razelle Kurzrock Division of Hematology/Oncology Department of Medicine University of California, San Diego Moores Cancer Center La Jolla, CA, USA
ISSN 2199-2584 ISSN 2199-2592 (electronic) Current Cancer Research ISBN 978-3-319-63756-3 ISBN 978-3-319-63757-0 (eBook) DOI 10.1007/978-3-319-63757-0 Library of Congress Control Number: 2017956906 © Springer International Publishing AG 2018 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer International Publishing AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
Preface
Immunotherapy: Transforming Cancer Care 1986: “Cancer is a wound that never heals”; 2017: “ The patient is both the host and the treatment for their cancer.”
While connoting both the social as well as biological consequences of an entity that has plagued mankind for millennia, this sentiment recognizes the central role of the immune system in wound healing, or, in this context, tumor elimination. The critical role that the immune system plays in tumor regression, and therapeutic strategies harnessing the host immune response against tumor, have been recognized since the advent of Coley’s toxin over a century ago—based on observations that patients with severe postoperative skin infections after their sarcoma surgery would spontaneously achieve can
Data Loading...
